92 related articles for article (PubMed ID: 21652010)
1. Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-β and interferon-β combined with low-dose oral steroids.
Sanvito L; Tomita A; Chihara N; Okamoto T; Lin Y; Ogawa M; Gran B; Aranami T; Yamamura T
J Neuroimmunol; 2011 Jul; 236(1-2):111-7. PubMed ID: 21652010
[TBL] [Abstract][Full Text] [Related]
2. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis.
Vandenbark AA; Huan J; Agotsch M; La Tocha D; Goelz S; Offner H; Lanker S; Bourdette D
J Neuroimmunol; 2009 Oct; 215(1-2):125-8. PubMed ID: 19758707
[TBL] [Abstract][Full Text] [Related]
3. Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy.
Martínez-Rodríguez JE; Saez-Borderías A; Munteis E; Romo N; Roquer J; López-Botet M
Clin Immunol; 2010 Oct; 137(1):41-50. PubMed ID: 20580616
[TBL] [Abstract][Full Text] [Related]
4. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
Sheridan JP; Zhang Y; Riester K; Tang MT; Efros L; Shi J; Harris J; Vexler V; Elkins JS
Mult Scler; 2011 Dec; 17(12):1441-8. PubMed ID: 21807759
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis.
Martínez-Rodríguez JE; López-Botet M; Munteis E; Rio J; Roquer J; Montalban X; Comabella M
Clin Immunol; 2011 Dec; 141(3):348-56. PubMed ID: 21992960
[TBL] [Abstract][Full Text] [Related]
6. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.
Johnson TA; Evans BL; Durafourt BA; Blain M; Lapierre Y; Bar-Or A; Antel JP
J Immunol; 2011 Jul; 187(1):570-9. PubMed ID: 21622858
[TBL] [Abstract][Full Text] [Related]
7. The regulatory role of natural killer cells in multiple sclerosis.
Takahashi K; Aranami T; Endoh M; Miyake S; Yamamura T
Brain; 2004 Sep; 127(Pt 9):1917-27. PubMed ID: 15229129
[TBL] [Abstract][Full Text] [Related]
8. [Different responses of CD94/NKG2A-bright and CD94/NKG2A-dim NK cell subsets isolated from patients with multiple sclerosis to interferon-beta].
Li L; Deng YC; Zhao G
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Jun; 23(6):533-5. PubMed ID: 17553351
[TBL] [Abstract][Full Text] [Related]
9. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
Fujimiya Y; Wagner RJ; Groveman S; Sielaff K; Kohsaka T; Nakayama M
Ther Immunol; 1995 Feb; 2(1):15-22. PubMed ID: 7553067
[TBL] [Abstract][Full Text] [Related]
10. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation.
Gigli G; Caielli S; Cutuli D; Falcone M
Immunology; 2007 Nov; 122(3):409-17. PubMed ID: 17617156
[TBL] [Abstract][Full Text] [Related]
11. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
12. Human natural killer cell subsets and acute exercise: a brief review.
Timmons BW; Cieslak T
Exerc Immunol Rev; 2008; 14():8-23. PubMed ID: 19203081
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
[TBL] [Abstract][Full Text] [Related]
14. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy.
Becher B; Giacomini PS; Pelletier D; McCrea E; Prat A; Antel JP
Ann Neurol; 1999 Feb; 45(2):247-50. PubMed ID: 9989628
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis.
Rodríguez-Martín E; Picón C; Costa-Frossard L; Alenda R; Sainz de la Maza S; Roldán E; Espiño M; Villar LM; Álvarez-Cermeño JC
Clin Exp Immunol; 2015 May; 180(2):243-9. PubMed ID: 25565222
[TBL] [Abstract][Full Text] [Related]
18. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
19. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor.
Benczur M; Petrányl GG; Pálffy G; Varga M; Tálas M; Kotsy B; Földes I; Hollán SR
Clin Exp Immunol; 1980 Mar; 39(3):657-62. PubMed ID: 6155232
[TBL] [Abstract][Full Text] [Related]
20. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
